Lantern Pharma Inc.
LTRN
$3.75
-$0.18-4.58%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.09M | -17.75M | -17.53M | -15.96M | -15.16M |
| Total Depreciation and Amortization | 303.50K | 259.30K | 216.50K | 174.80K | 151.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -232.50K | 303.50K | 750.90K | 902.10K | 1.34M |
| Change in Net Operating Assets | 1.79M | 1.93M | 2.91M | 538.00K | 39.10K |
| Cash from Operations | -17.23M | -15.26M | -13.66M | -14.35M | -13.63M |
| Capital Expenditure | -14.60K | -16.40K | -12.10K | -18.80K | -20.70K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 192.90K | -254.00K | -513.40K | -911.40K | -562.90K |
| Cash from Investing | 178.20K | -270.40K | -525.50K | -930.20K | -583.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 66.70K | 54.70K | 54.70K | -- | 0.00 |
| Repurchase of Common Stock | -500.00K | -500.00K | -500.00K | -500.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -433.30K | -445.30K | -445.30K | -500.00K | 0.00 |
| Foreign Exchange rate Adjustments | 12.90K | -15.50K | -33.20K | -28.40K | -13.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.47M | -15.99M | -14.66M | -15.81M | -14.23M |
